Back

Interleukin-1 receptor 8 deficiency enhances the anti-tumour activity of doxorubucin and reduces cardiotoxicity

20 June 2026 (13:15 - 14:15)
Organised by: Logo
Congress Presentation Part of: Mechanisms and investigational therapies of anthracycline cardiotoxicity Research and New Technology Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Francesco Scavello

Humanitas Research Hospital, Rozzano (Italy)

4 More presentations in this session

Presentation thumbnail
HDAC inhibition via suberoylanilide hydroxamic acid (SAHA) ameliorates doxorubicin-induced cardiotoxicity
Mrs B. Eksi (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Targeting the PKR1 pathway and the ROS/NRF/PK2 axis for cardioprotection and biomarker discovery in anthracycline therapy
Professor C. Nebigil (Strasbourg, FR)
Abstract Slides
Presentation thumbnail
Hemopexin mitigates doxorubicin cardiotoxicity by preserving cardiac metabolism while maintaining antitumor efficacy in a mouse model of breast cancer
Doctor G. Guerra (Turin, IT)
Abstract Slides
Presentation thumbnail
ATNFAIP8--dependent survival axis protects cardiomyocytes from anthracycline-induced cardiotoxicity
Professor Y. Liu (Tainan, TW)
Abstract Slides

Access the full session

Session thumbnail
Mechanisms and investigational therapies of anthracycline cardiotoxicity

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 13:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources